J Korean Diabetes.  2016 Jun;17(2):106-111. 10.4093/jkd.2016.17.2.106.

Development of a Checklist for the Detection of Lipohypertrophy at Insulin Injection Sites

• Hong M
• Kim Y
• Lim K

• KMID: 2328575
• DOI: http://doi.org/10.4093/jkd.2016.17.2.106

Abstract

Lipohypertrophy refers to the phenomenon of subcutaneous fatty tissue becoming either softer or firmer than normal so that it becomes thickened. The presence of lipohypertrophy is associated with not rotating injection sites correctly, injecting into the same sites repeatedly, using smaller injection zones, and reusing needles. Injecting into lipohypertrophy sites can cause unexplained hypoglycemia because insulin absorption is delayed or erratic, thus potentially worsening glucose levels and even diabetes management. Therefore, developing a lipohypertrophy checklist for patients who inject insulin is necessary to detect lipohypertrophy as soon as possible in order to avoid repeatedly injecting into lipohypertrophy sites. A lipohypertrophy checklist will help patients maintain stable glucose levels by minimizing the risk of glycemic variability.

Keyword

Checklist; Insulin injection site; Lipohypertrophy

MeSH Terms

Absorption
Adipose Tissue
Checklist*
Glucose
Humans
Hypoglycemia
Insulin*
Needles
Glucose
Insulin

Reference

References

1. Korean Diabetes Association. Diabetes. 4th ed.Seoul: Korea Medical Book;2011. p432.

2. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996; 104:106–10.

3. Saez-de lbarra L, Gallego F. Factors related to lipohypertrophy in insulin treated diabetic patients: role of educational intervention. Pract Diabetes Int. 1998; 15:9–11.

4. Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract. 1992; 16:209–12.

5. Torrance T. An unexpected hazard of insulin injection. Pract Diabetes Int. 2002; 19:63.

6. Hong MH, Gu MJ, Yoo JH, Jung EK. Korean Association Diabetic Nurse Educators. Insulin injection guideline for diabetes educators. Seoul: Korean Association Diabetic Nurse Educators;2010. p. 105–10.

7. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013; 39:445–53.

8. Volkova NI, Davidenko IY. Lypohypertrophy in patients receiving insulin therapy: state of the art. Diabetes Mellit. 2011; 2:86–9.

9. Hambridge K. The management of lipohypertrophy in diabetes care. Br J Nurs. 2007; 16:520–4.

10. Seyoum B, Abdulkadir J. Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. Trop Doct. 1996; 26:159–61.

11. Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane (NPH) insulin. Diabet Med. 1990; 7:795–9.

12. Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007; 77:231–6.